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Abstract
The increased attention to design and analysis of randomised clinical trials in small populations has triggered thinking
regarding the most appropriate design methods for a particular clinical research question. Decision schemes and
algorithms have been proposed, with varying starting points and foci. Parmar et al. (BMC Medicine 14:183, 2016)
proposed a framework designed to assist the clinical trial team in design choices during protocol preparation. Herein,
further stimulus is given regarding the extent to which a framework may help change practice for the better, the
careful considerations for changing the usual error levels applied and the room for innovation in clinical trial design.
Please see related article: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-016-0722-3.
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Background
The increased attention to design and analysis of ran-
domised clinical trials in small populations has trig-
gered thinking regarding the processes leading to the
most appropriate design for a particular clinical re-
search question. In common diseases, this might not
seem a pressing problem, given the extensive practice-
and theory-based experience in trial designs. In the
context of drug development for rare diseases, guidance
from the European Medicines Agency [1] states that “in
conditions with small and very small populations, less
conventional and/or less commonly seen methodological
approaches may be acceptable if they help to improve
the interpretability of the study results”. However, this
advice does not provide practical guidance on how such
choices can be made at the clinical trial designing stage.
Moreover, it also states that “[n]o methods exist that
are relevant to small studies that are not also applic-
able to large studies” [1]. Hence, such practical guid-
ance is actually relevant for all trials. Thus, there is
arguably a need for a design framework, with that pro-
posed by Parmar, Sydes and Morris [2] having
particularly strong points. Their framework follows a
logical order of the steps one would take in designing a
trial, allowing for practical implementation. Secondly, it
is driven by what could be termed a ‘step-down ap-
proach’: at each step following a non-feasible option,
the next potential change or comprise to be considered
is the one with minimal impact on the objective of
obtaining high quality randomised evidence to improve
care for the target patient population. It also appropri-
ately addresses the fact that designing a clinical trial is
a complex multidisciplinary and multifaceted exercise,
not easily captured in a simple decision scheme.
Frameworks (or even algorithms) for applying particu-
lar designs for randomised clinical trials in small popula-
tions have been previously proposed, notably by Gupta
et al. [3] and Cornu et al. [4], both of which are based
on a literature search up to 2010, a particular choice of
decision ‘nodes’ and considerations of the pros and cons
of (less familiar) designs. The decision nodes are driven
by the type of intervention [3], type of outcome versus
recruitment time [3, 4], feasibility of sample size [3],
prior knowledge and treatment alternatives [3], and cer-
tain design desirabilities [4]. Further, they address mini-
mising time on placebo, and/or ensuring that all
participants are on active treatment at the end of the
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trial [4]. In these frameworks, it is actually difficult to as-
certain whether a particular choice is (in some sense)
the best possible given the circumstances. Indeed, the
focus of Parmar et al.’s [2] framework on the ‘best’ ran-
domised evidence to improve care for patients makes
the search for this ‘best possible’ far more explicit. We
concur that this requires the time and adequate atten-
tion of the entire clinical research team. If application of
a framework helps to concentrate the team in order to
design the best possible trial, this is, in itself, a positive
effect not to be underestimated, particularly for
investigator-initiated trials.
Herein, the proposed framework and its application
are further considered, focusing on the level of ambition
for its practical application, a discussion on relaxing type
I or II errors, and the methods through which a deeper
understanding of novel trial designs may be obtained.
Frameworks as a starting point or to change
practice for the better
In several instances, Parmar et al. [2] refer to standard
practice as ‘traditional’ with an undoubtedly positive
connotation. Rightfully so, many current practices in
trial design are thoroughly founded on theory as well as
extensive practical application. However, that does not
hold for all framework aspects, and not all aspects im-
prove clinical trial statistical efficiency. It is important to
consider how the framework is best positioned for appli-
cation. If it aims to stay as close possible to current prac-
tice (‘traditional’) to stimulate its use, the proposed
ordering is acceptable. However, in clinical trial method-
ology there are a number of current practices that we
(as statisticians) know are not optimal, but which are
difficult to change in real life. One could argue that ap-
plication of a framework is an opportunity to influence
less optimal practices. Therefore, this could lead to some
changes within the framework.
Two approaches labelled as ‘less common’ are (1) in-
cluding covariate information and (2) moving from two-
to one-sided significance tests; this really seems a missed
opportunity to influence practice. Regarding the inclu-
sion of covariate information, it is (by now) well ac-
cepted that including relevant prognostic covariates into
the primary analysis will most likely increase power, and
should be considered for any trial at the initial design
stage. However, it remains at the ‘recommendation for
improvement’ stage in small population trials [5]. On the
same note, stratification of the randomisation is usually
considered for every trial. For small populations, there
are clear limits to the amount of ‘traditional’ stratifica-
tion that can be performed. Both stratification and
inclusion of covariate information should therefore be
considered in concert for any trial at an early stage [6],
which can be carried out fairly independently of the
other trial features.
It is beyond the scope of this commentary (and maybe
also beyond the author’s competence) to fully cover the
discussion on one- or two-sided testing. What can be
noted, however, is that group sequential and adaptive
clinical trials can only be appropriately designed and
understood with one-sided testing [7]. Given the wide-
spread use of these flexible designs it could be con-
cluded that this debate has effectively ended, as long as
the ‘standard’ one-sided α-level is 2.5%. Other choices
(ie moving to 5% one-sided) would then fall under a re-
laxation of the α-level.
Relaxing power, relaxing the α-level
Parmar et al. [2] provide a thoughtful discussion on
carefully relaxing the power or α, which is a particularly
strong point in their framework. Relaxing the power and
α-level strongly relates to the (theoretical) reproducibil-
ity of the trial. Society expects that research results are
reliable, with even greater pressure when vulnerable pa-
tients have contributed to the research. Expressed con-
cerns on reliability of research in general, and medical
research in particular, have raised awareness on the rigor
of design that is required [8]. One of the areas for
improvement indicated is striking the right balance of
clinically relevant outcomes, power and α-level. A care-
ful approach, particularly in small populations, seems to
be on the right direction.
Deeper understanding of novel trial designs
Novel design and analysis approaches for small popula-
tions are expected to be beneficial in clinical research
aimed at improving care for patients [9, 10]. A deeper
understanding of the properties of such designs needs
research as well as lessons learned from actual applica-
tion. Our current deep level of understanding of the ins
and outs of clinical trial design has only been reached
because of a continuous cycle of improvement between
theory development and real-life application. Hence,
there is long-term benefit – beyond the level of an indi-
vidual trial – of ‘road testing’ novel design features that
hold strong promise of improvement based on theory. It
will be worthwhile to consider whether application of a
framework, as proposed, retains sufficient opportunity to
experiment with trial design.
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